Organon & Co. (OGN) to Release Quarterly Earnings on Thursday

Organon & Co. (NYSE:OGN) is set to announce its earnings results before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of $1.05 per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Thursday, February 15th. The company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.14. The company had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.55 billion. Organon & Co. had a negative return on equity of 212.00% and a net margin of 16.33%. On average, analysts expect Organon & Co. to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Organon & Co. Stock Performance

Shares of OGN opened at $18.61 on Wednesday. The company has a market capitalization of $4.79 billion, a PE ratio of 4.65, a price-to-earnings-growth ratio of 0.88 and a beta of 0.82. The stock has a fifty day moving average of $18.14 and a two-hundred day moving average of $15.70. Organon & Co. has a fifty-two week low of $10.84 and a fifty-two week high of $24.79.

Organon & Co. Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 14th. Stockholders of record on Monday, February 26th were issued a dividend of $0.28 per share. The ex-dividend date was Friday, February 23rd. This represents a $1.12 dividend on an annualized basis and a dividend yield of 6.02%. Organon & Co.’s payout ratio is 28.00%.

Insider Activity

In other Organon & Co. news, insider Kirke Weaver acquired 2,720 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The shares were purchased at an average price of $18.36 per share, for a total transaction of $49,939.20. Following the completion of the purchase, the insider now directly owns 15,181 shares in the company, valued at $278,723.16. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 1.17% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on OGN shares. The Goldman Sachs Group upped their price objective on Organon & Co. from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Tuesday, February 20th. Piper Sandler upped their price target on shares of Organon & Co. from $22.00 to $24.00 and gave the stock an “overweight” rating in a research report on Monday.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.